INBX vs TGTX vs IMVT vs RCUS vs KYMR

For growth investors, Inhibrx Biosciences, Inc.

(INBX) is the stronger pick with 550. 0% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 9x forward), making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Inhibrx Biosciences, Inc.

(INBX) delivered a total return of +812. 9%, compared to -12. 1% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: INBX returned +555. 4% versus RCUS's +49. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 84β versus Inhibrx Biosciences, Inc. 's 1. 99β — meaning INBX is approximately 139% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for Inhibrx Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Inhibrx Biosciences, Inc.

(INBX) is pulling ahead at 550. 0% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -107. 8% for Inhibrx Biosciences, Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -107. 7% for Inhibrx Biosciences, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -103. 9% for INBX. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 57.

2% to $45. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TG Therapeutics, Inc.

(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84), +434. 4% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +434. 4%, RCUS: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INBX is a small-cap high-growth stock; TGTX is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.